When to Discontinue IV Albumin in Hepatorenal Syndrome
Discontinue IV albumin in HRS-AKI when creatinine clearance rises above 40 mL/min or serum creatinine falls below 132 µmol/L (approximately 1.5 mg/dL), indicating treatment response. 1
Treatment Duration and Response Assessment
The standard albumin regimen for HRS-AKI involves:
- Initial volume expansion: 1 g/kg daily for 2 consecutive days (maximum 100 g/day) 2
- With vasoconstrictors: Continue albumin throughout vasoconstrictor therapy until response or treatment failure
Defining Treatment Response
Stop albumin when patients achieve either endpoint 1:
- Creatinine clearance >40 mL/min, OR
- Serum creatinine <132 µmol/L (1.5 mg/dL)
Critical Timing Considerations
Recent evidence strongly supports continuing albumin for 48 hours rather than stopping at 24 hours 3. A significant proportion of responses to albumin occur between 24-48 hours, and premature discontinuation may miss potential responders. The newer 2024 AGA guidelines 2 and recent 2025 data 3 challenge earlier recommendations to limit albumin to 24 hours.
Context-Specific Stopping Points
For HRS-AKI with Vasoconstrictors
Continue albumin throughout the vasoconstrictor course (typically up to 14-15 days) unless 4:
- Treatment response achieved (see criteria above)
- Volume overload develops (pulmonary edema, respiratory failure)
- Treatment failure declared (no improvement after maximum therapy duration)
For AKI Without Confirmed HRS
After the initial 48-hour diagnostic trial 2, 3:
- Stop if HRS-AKI is ruled out and another AKI etiology is identified
- Continue if HRS-AKI is confirmed and initiate vasoconstrictors
For Spontaneous Bacterial Peritonitis
Use the fixed regimen 2:
- Day 1: 1.5 g/kg
- Day 3: 1.0 g/kg
- Then stop (total 2 doses only)
Safety Monitoring: When to Stop Due to Complications
Immediately discontinue albumin if 2, 5, 6:
- Pulmonary edema or respiratory failure develops
- Fluid overload with clinical decompensation
- Cardiovascular complications (though these are more commonly related to vasoconstrictors)
Important Caveat on High-Dose Albumin
Recent data suggests that doses >50 g/day in severe HRS-AKI with infection may be safe and not associated with worse respiratory outcomes 6. However, this requires careful patient selection and monitoring. The key is clinical assessment for volume overload rather than arbitrary dose limits.
Practical Algorithm
- Days 0-2: Give albumin 1 g/kg/day (max 100 g/day) for volume expansion
- At 48 hours: Assess response
- If creatinine improved to <1.5 mg/dL or CrCl >40 mL/min → STOP
- If HRS-AKI confirmed → Continue albumin + start vasoconstrictors
- If other AKI cause identified → STOP albumin
- Days 3-14: Continue albumin with vasoconstrictors, monitoring daily for:
- Treatment response (stop when achieved)
- Volume overload (stop if develops)
- Maximum treatment duration reached (typically 14-15 days)
Common Pitfalls to Avoid
- Don't stop at 24 hours in potential HRS-AKI cases—wait the full 48 hours 3
- Don't continue indefinitely in non-responders—reassess diagnosis and consider treatment failure
- Don't use fixed protocols blindly—tailor albumin dose to volume status, though CVP-guided therapy 1 is not widely adopted in current guidelines
- Don't forget to stop after the 2-dose SBP regimen—continuing beyond day 3 in SBP is not indicated 2
The 2024 AGA guidelines 2 represent the most current expert consensus, emphasizing that albumin should be continued for 48 hours during diagnostic evaluation and throughout vasoconstrictor therapy for confirmed HRS-AKI, with discontinuation based on clinical response rather than arbitrary time limits.